Meeting
2022 ASCO Annual Meeting
Reasons for oncologist and urologist treatment choice in metastatic castration-sensitive prostate cancer (mCSPC): A physician survey linked to patient chart reviews in the United States.
Authors
Stephen J. Freedland
Division of Urology, Department of Surgery, Cedars-Sinai Medical Center and Department of Surgery, Durham Veterans Affairs Health Care System, Durham, NC
Stephen J. Freedland , Zachary William Abraham Klaassen , Neeraj Agarwal , Rickard Sandin , Andrea Leith , Amanda Ribbands , Emily Clayton , Jake Butcher , Liane Gillespie-Akar , Dave Russell , Agnes Hong , Krishnan Ramaswamy , Daniel J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5065)
DOI
10.1200/JCO.2022.40.16_suppl.5065
Abstract #
5065
Poster Bd #
248
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.
First Author: Kim N. Chi
Poster
2023 ASCO Annual Meeting
Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle F Burgess
Poster
2022 ASCO Annual Meeting
![The association of germline<em> HSD3B1</em> genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].](https://d201v5jt9ylckg.cloudfront.net/288/14370/212152/212152_A1803_poster_pv.jpg)
The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].
First Author: Nima Sharifi
Poster
2022 ASCO Genitourinary Cancers Symposium
Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT).
First Author: Umang Swami